{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T10:41:54Z","timestamp":1777977714116,"version":"3.51.4"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:00:00Z","timestamp":1702425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.autrev.2023.103481","type":"journal-article","created":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T17:05:45Z","timestamp":1700845545000},"page":"103481","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["New onset sarcoidosis following biologic treatment in patients with seronegative inflammatory arthritis: A case series and systematic literature review"],"prefix":"10.1016","volume":"23","author":[{"given":"Denise","family":"Donzella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Bellis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Campisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria","family":"Crepaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Data","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Dapavo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Lomater","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Marucco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Saracco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariele","family":"Gatto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annamaria","family":"Iagnocco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.autrev.2023.103481_bb0005","first-page":"696","article-title":"Sarcoidosis: an old but always challenging disease","volume":"11","author":"Tana","year":"2021","journal-title":"Diagn Basel Switz"},{"issue":"7","key":"10.1016\/j.autrev.2023.103481_bb0010","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/17512433.2018.1486706","article-title":"Treatment of sarcoidosis: grading the evidence","volume":"11","author":"James","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103481_bb0015","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1177\/12034754221100187","article-title":"Onset of sarcoidosis in patients on biologic therapy: a systematic review","volume":"26","author":"Lytvyn","year":"2022","journal-title":"J Cutan Med Surg"},{"issue":"16","key":"10.1016\/j.autrev.2023.103481_bb0020","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1001\/jama.2015.3656","article-title":"Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement","volume":"313","author":"Stewart","year":"2015","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.autrev.2023.103481_bb0025","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/art.21336","article-title":"Granulomatous lung disease occurring during etanercept treatment","volume":"53","author":"Phillips","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.autrev.2023.103481_bb0030","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/art.22351","article-title":"Pulmonary sarcoidosis developing during infliximab therapy","volume":"55","author":"O\u2019shea","year":"2006","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.autrev.2023.103481_bb0035","first-page":"99","article-title":"Pulmonary sarcoidosis in a patient with ankylosing spondylitis treated with infliximab","volume":"25","author":"Almod\u00f3var","year":"2007","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103481_bb0040","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/art.22238","article-title":"Development of sarcoidosis during etanercept therapy","volume":"55","author":"Gonz\u00e1lez-L\u00f3pez","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.autrev.2023.103481_bb0045","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1592\/phco.27.10.1446","article-title":"Pulmonary sarcoidosis associated with etanercept therapy","volume":"27","author":"Farah","year":"2007","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.autrev.2023.103481_bb0050","first-page":"1222","article-title":"Cutaneous granulomas during infliximab therapy for spondyloarthropathy","volume":"35","author":"Dubosc","year":"2008","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103481_bb0055","first-page":"471","article-title":"Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases","volume":"26","author":"Toussirot","year":"2008","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2023.103481_bb0060","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/j.1365-4632.2009.04080.x","article-title":"Facial granulomatous nodules during etanercept treatment for psoriasis","volume":"48","author":"Samimi","year":"2009","journal-title":"Int J Dermatol"},{"issue":"8","key":"10.1016\/j.autrev.2023.103481_bb0065","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/rheumatology\/kep046","article-title":"Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases","volume":"48","author":"Daien","year":"2009","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.autrev.2023.103481_bb0070","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000275676","article-title":"Cutaneous sarcoidosis occurring during anti-TNF-alpha treatment: report of two cases","volume":"220","author":"Dhaille","year":"2010","journal-title":"Dermatology"},{"issue":"4","key":"10.1016\/j.autrev.2023.103481_bb0075","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00296-009-1349-x","article-title":"Development of sarcoidosis following etanercept treatment: a report of three cases","volume":"32","author":"Skoie","year":"2012","journal-title":"Rheumatol Int"},{"issue":"6","key":"10.1016\/j.autrev.2023.103481_bb0080","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1053\/j.ajkd.2010.08.019","article-title":"Drug-induced granulomatous interstitial nephritis in a patient with ankylosing spondylitis during therapy with adalimumab","volume":"56","author":"Korsten","year":"2010","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.autrev.2023.103481_bb0085","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.semarthrit.2008.11.003","article-title":"Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new \u201cclass effect\u201d paradoxical phenomenon. Two case reports and literature review","volume":"39","author":"Massara","year":"2010","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2023.103481_bb0090","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10067-010-1577-1","article-title":"Tumor necrosis factor-alpha (TNF-\u03b1)-blockade-induced hepatic sarcoidosis in psoriatic arthritis (PsA): case report and review of the literature","volume":"30","author":"Cuchacovich","year":"2011","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103481_bb0095","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1445-5994.2011.02612.x","article-title":"New onset sarcoid-like granulomatosis developing during anti-TNF therapy: an under-recognised complication","volume":"42","author":"Tong","year":"2012","journal-title":"Intern Med J"},{"issue":"3","key":"10.1016\/j.autrev.2023.103481_bb0100","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1111\/j.1440-0960.2010.00660.x","article-title":"Development of sarcoidosis during adalimumab therapy for chronic plaque psoriasis: TNF antagonist-associated sarcoidosis","volume":"52","author":"Marcella","year":"2011","journal-title":"Australas J Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103481_bb0105","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3109\/09273948.2011.623212","article-title":"Sarcoid intermediate uveitis following etanercept treatment: a case report and review of the literature","volume":"20","author":"Fonollosa","year":"2012","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"10.1016\/j.autrev.2023.103481_bb0110","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.amjoto.2012.12.016","article-title":"Sarcoidosis-like granulomatosis of the hypopharynx as a complication of anti-TNF therapy","volume":"34","author":"Christoforidou","year":"2013","journal-title":"Am J Otolaryngol"},{"issue":"4","key":"10.1016\/j.autrev.2023.103481_bb0115","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1111\/j.1440-0960.2011.00863.x","article-title":"Development of cutaneous sarcoidosis during treatment with tumour necrosis alpha factor antagonists: sarcoidosis with TNF-alpha antagonists","volume":"53","author":"Lamrock","year":"2012","journal-title":"Australas J Dermatol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103481_bb0120","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jbspin.2013.07.014","article-title":"Sarcoidosis onset during TNF\u03b1-antagonist therapy: is infection the culprit?","volume":"80","author":"Verhoeven","year":"2013","journal-title":"Joint Bone Spine"},{"issue":"4","key":"10.1016\/j.autrev.2023.103481_bb0125","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s00393-016-0262-4","article-title":"Adalimumab-induced pulmonary sarcoidosis not progressing upon treatment with etanercept","volume":"76","author":"Jung","year":"2017","journal-title":"Z Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103481_bb0130","doi-asserted-by":"crossref","first-page":"67","DOI":"10.5606\/ArchRheumatol.2017.6055","article-title":"A rare adverse effect of anti-tumor necrosis factor alpha therapy: sarcoidosis","volume":"32","author":"Mengi","year":"2017","journal-title":"Arch Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2023.103481_bb0135","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jbspin.2018.05.001","article-title":"Muscular sarcoidosis under anti-TNF treatment in ankylosing spondylitis","volume":"85","author":"Wendling","year":"2018","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.autrev.2023.103481_bb0140","first-page":"1","article-title":"Pulmonary sarcoidosis following etanercept treatment for ankylosing spondylitis: a case report and review of the literature","volume":"2018","author":"Majjad","year":"2018","journal-title":"Case Rep Rheumatol"},{"issue":"10","key":"10.1016\/j.autrev.2023.103481_bb0145","doi-asserted-by":"crossref","DOI":"10.1111\/1346-8138.14893","article-title":"Adalimumab as a successful alternative for the treatment of infliximab-induced sarcoidosis","volume":"46","author":"Ando","year":"2019","journal-title":"J Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103481_bb0150","first-page":"344","article-title":"Safety of the use of anti-IL17A treatment in a patient with certolizumab-induced sarcoidosis","volume":"37","author":"Toussirot","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103481_bb0155","first-page":"23","article-title":"Pulmonary sarcoidosis induced by anti-tumor necrosis factor therapy: a paradoxical effect","volume":"26","author":"Pugliesi","year":"2020","journal-title":"J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis"},{"issue":"10","key":"10.1016\/j.autrev.2023.103481_bb0160","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.16451","article-title":"Development or worsening of sarcoidosis associated with IL-17 blockade for psoriasis","volume":"34","author":"Hornick","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.autrev.2023.103481_bb0165","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1080\/09273948.2020.1850799","article-title":"Drug-induced sarcoid uveitis with biologics","volume":"30","author":"Sobolewska","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.autrev.2023.103481_bb0170","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.15986","article-title":"A case of adalimumab-induced granulomatous interstitial nephritis","author":"Plant","year":"2021","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.autrev.2023.103481_bb0175","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4103\/2452-2325.312161","article-title":"Sarcoid-associated bilateral multifocal choroiditis secondary to adalimumab","volume":"33","author":"Wilkins","year":"2021","journal-title":"J Curr Ophthalmol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103481_bb0180","doi-asserted-by":"crossref","first-page":"e240615","DOI":"10.1136\/bcr-2020-240615","article-title":"Sarcoidosis manifesting during treatment with secukinumab for psoriatic arthritis","volume":"14","author":"Kirby","year":"2021","journal-title":"BMJ Case Rep"},{"issue":"12","key":"10.1016\/j.autrev.2023.103481_bb0185","doi-asserted-by":"crossref","first-page":"e01065","DOI":"10.1002\/rcr2.1065","article-title":"Pulmonary sarcoidosis with a cavitary lesion in the lung caused by a TNF -\u03b1 inhibitor: a case report","volume":"10","author":"Hamada","year":"2022","journal-title":"Respirol Case Rep"},{"issue":"12","key":"10.1016\/j.autrev.2023.103481_bb0190","doi-asserted-by":"crossref","first-page":"omac133","DOI":"10.1093\/omcr\/omac133","article-title":"Renal sarcoidosis associated with certolizumab pegol treatment for psoriatic arthritis","volume":"2022","author":"Hum","year":"2022","journal-title":"Oxf Med Case Rep"},{"key":"10.1016\/j.autrev.2023.103481_bb0195","doi-asserted-by":"crossref","DOI":"10.4081\/monaldi.2022.2343","article-title":"Sarcoidosis-like reaction secondary to adalimumab treatment in a patient with axial spondyloarthritis","author":"Gon\u00e7alves Pimenta","year":"2022","journal-title":"Monaldi Arch Chest Dis"},{"issue":"16","key":"10.1016\/j.autrev.2023.103481_bb0200","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.2169\/internalmedicine.4275-19","article-title":"Systemic sarcoidosis associated with certolizumab pegol treatment for rheumatoid arthritis: a case report and review of the literature","volume":"59","author":"Koda","year":"2020","journal-title":"Intern Med Tokyo Jpn"},{"issue":"11","key":"10.1016\/j.autrev.2023.103481_bb0205","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1111\/jdv.13246","article-title":"TNF-\u03b1: a treatment target or cause of sarcoidosis?","volume":"29","author":"Amber","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.autrev.2023.103481_bb0210","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1055\/s-0030-1262208","article-title":"Immunologic response of sarcoidosis","volume":"31","author":"Zissel","year":"2010","journal-title":"Semin Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.autrev.2023.103481_bb0215","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.chest.2017.11.030","article-title":"The pathogenesis of pulmonary sarcoidosis and implications for treatment","volume":"153","author":"Patterson","year":"2018","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.autrev.2023.103481_bb0220","first-page":"70","article-title":"Infliximab for refractory sarcoidosis","volume":"18","author":"Baughman","year":"2001","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG"},{"issue":"1","key":"10.1016\/j.autrev.2023.103481_bb0225","doi-asserted-by":"crossref","first-page":"27","DOI":"10.7326\/0003-4819-135-1-200107030-00010","article-title":"Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy","volume":"135","author":"Yee","year":"2001","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.autrev.2023.103481_bb0230","first-page":"91","article-title":"Practical eminence and experience-based recommendations for use of TNF-\u03b1 inhibitors in sarcoidosis","volume":"31","author":"Drent","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG"},{"issue":"6","key":"10.1016\/j.autrev.2023.103481_bb0235","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.semarthrit.2018.10.005","article-title":"Anti-tumor necrosis factor agents in sarcoidosis: a systematic review of efficacy and safety","volume":"48","author":"Adler","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2023.103481_bb0240","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1086\/505430","article-title":"Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity","volume":"194","author":"Saliu","year":"2006","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.autrev.2023.103481_bb0245","doi-asserted-by":"crossref","first-page":"e000239","DOI":"10.1136\/rmdopen-2015-000239","article-title":"Paradoxical reactions under TNF-\u03b1 blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview","volume":"2","author":"Toussirot","year":"2016","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.autrev.2023.103481_bb0250","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000358324","article-title":"Certolizumab-induced uveitis: a case report and review of the literature","volume":"5","author":"Moisseiev","year":"2014","journal-title":"Case Rep Ophthalmol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103481_bb0255","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1600-0560.2011.01795.x","article-title":"Etanercept-induced cutaneous and pulmonary sarcoid-like granulomas resolving with adalimumab","volume":"39","author":"Burns","year":"2012","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.autrev.2023.103481_bb0260","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-200552","article-title":"Sarcoid panuveitis associated with etanercept treatment, resolving with adalimumab","volume":"2013","author":"Dragnev","year":"2013","journal-title":"BMJ Case Rep"},{"issue":"9","key":"10.1016\/j.autrev.2023.103481_bb0265","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.16416","article-title":"Interleukin-17 blockade downregulates NOD2 in skin and may promote paradoxical sarcoidosis","volume":"34","author":"Wang","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.autrev.2023.103481_bb0270","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/ced.14101","article-title":"Management with secukinumab of tumour necrosis factor inhibitor-induced pulmonary sarcoidosis-like reaction in a patient with psoriasis","volume":"45","author":"Eichhoff","year":"2020","journal-title":"Clin Exp Dermatol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899722300215X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899722300215X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T06:29:19Z","timestamp":1715063359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156899722300215X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S156899722300215X"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103481","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New onset sarcoidosis following biologic treatment in patients with seronegative inflammatory arthritis: A case series and systematic literature review","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103481","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103481"}}